Filing Flows › Teva Pharmaceutical Industries (TEVA) › Free cash flow
Teva Pharmaceutical Industries (TEVA) free cash flow by quarter
Teva Pharmaceutical Industries' free cash flow was $121M in Q3 2026 (third quarter 2026), -61% from Q2 2026. Over the last 5 quarters it ranged from $121M (Q3 2026) to $1.0B (Q4 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $121M | -61% | -48% |
| Q2 2026 | $307M | -70% | +134% |
| Q4 2025 | $1.0B | +336% | — |
| Q3 2025 | $233M | +78% | — |
| Q2 2025 | $131M | — | — |
Q3 2026 at a glance
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
What is Teva Pharmaceutical Industries' free cash flow?
Teva Pharmaceutical Industries' free cash flow was $121M in Q3 2026 (third quarter 2026), -61% from Q2 2026.
How has Teva Pharmaceutical Industries' free cash flow changed?
Over the last 5 quarters it ranged from $121M (Q3 2026) to $1.0B (Q4 2025).
Q3 2026 results → · How Teva Pharmaceutical Industries makes money →